Agah Ramtin purchased $46K of RNXT

Agah Ramtin (Executive Chairman and CMO) purchased 50,000 shares of RenovoRx, Inc. (RNXT) at $0.93 on 2026-11-16.

Original reporting
SEC EDGAR · Agah Ramtin
Published Nov 17, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RNXTBullishLow
01

Why it matters

The disclosed open-market purchase may be interpreted as bullish by some traders, but the article contains no new operational, clinical, regulatory, or financial catalyst.

02

Market read

Traders may monitor RNXT for follow-on insider activity, but this filing alone is unlikely to materially change valuation expectations.

03

What to watch

The filing provides no context on motivation, timing constraints, or whether the purchase was part of a broader pattern of insider activity.

Relevance 4/10Novelty 5/10Timing: filed today on SEC EDGAR, but transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for RenovoRx, Inc. (RNXT).

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx insider Agah Ramtin bought 50,000 shares at $0.9297 on 2026-11-16, per a new SEC Form 4 filed 2026-11-17.

Expected impact

Likely mild sentiment support, with limited follow-through unless accompanied by other catalysts.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, but the disclosed dollar value is modest and there is no 10b5-1 plan or other accompanying fundamental update in the text.

Market effects

No clear sector read-through from a single, modest insider purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions, especially when not tied to a 10b5-1 plan disclosure in the article.

Key entities

  • RenovoRx, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Agah Ramtin

    Executive Chairman and CMO who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RNXTMed

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.